Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.18    0.00 (0.00%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £2.38m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Convertible Loan Note Offer

18 Jul 2006 15:48

Azure Holdings PLC18 July 2006 Azure Holdings plc (the "Company") Convertible Loan Note Offer The Company announces that it has today issued a letter to holders of ordinaryshares of 1p each in the Company ("Ordinary Shares"), on the share register ofthe Company on 17 July 2006, offering them the opportunity to participate in thesubscription of up to £1,200,000 nominal unsecured convertible loan stock 2008("Loan Stock"). The Loan Stock is being offered following discussions regarding a proposedacquisition by the Company ("Acquisition"). The proposed target for theAcquisition is ValiRX Limited ("ValiRX"), a biopharmaceutical developmentcompany. Discussions with ValiRX are progressing and the directors of theCompany hope to complete a reverse takeover under the AIM rules before 30September 2006. The principal terms of the Loan Stock are as follows: 1 Unless previously converted or repaid, the Loan Stock isrepayable 24 months from the date of the Loan Stock instrument under which it iscreated (the "Instrument") or at any time after 31 October 2006 at the Company'soption. 2 In partial consideration for the Loan Stock holderssubscribing for Loan Stock, a premium ("Premium") of £2 for each £1 nominal ofLoan Stock is payable, unless previously converted or paid, 24 months from thedate of the Instrument, or at any time after 31 October 2006 at the Company'soption. 3 Interest is payable from 1 November 2006 on the amount ofthe Loan Stock at the rate of two per cent. over the base rate of the Bank ofScotland plc from time to time. Interest is payable twice yearly. The firstinterest period will run from 1 November 2006 to 31 March 2007. 4 The conversion of Loan Stock ("Conversion") into OrdinaryShares is conditional upon approval by shareholders of resolutions to allotshares and disapply pre-emption rights; and if appropriate, the approval by avote of independent shareholders taken on a poll of any waiver granted by thePanel on Takeovers and Mergers of any obligation under rule 9 of the City Codeon Takeovers and Mergers which may arise from such Conversion (together the "Conversion Event") 5 Immediately prior to the Conversion Event, the Loan Stockis deemed repayable and the Premium is deemed payable. 6 On the Conversion Event, the Loan Stock and the Premiumwhich has not been repaid or paid as the case may be, will be converted intoOrdinary Shares in the capital of the Company at the rate of 100 Ordinary Sharesof the Company for each £1 otherwise due for repayment or payment. 7 So far as it is lawfully able to do so, the Company willnotify the Loan Stock holders at least 10 days in advance of the likelyoccurrence of the Conversion Event. 8 The Loan Stock is transferable in multiples of £10,000. 9 The Company is obliged to repay the Loan Stock and pay thePremium on the occurrence of certain events, including certain insolvencyevents. 10 Decisions relating to the Loan Stock are to be taken by a writtenresolution of the holders of at least two thirds in nominal value of theoutstanding Loan Stock. Applications for the Loan Stock may only be made for a minimum of £1,000 nominaland in multiples of £1,000. Applications for the Loan Stock are to be receivedby the Company at One Great Cumberland Place, London W1H 7AL by 3.00pm on 31July 2006. A copy of the letter despatched to shareholders and the Instrument are availablefor inspection, on request, at Halliwells LLP, 1 Threadneedle Street, LondonEC2R 8AW during normal business hours on any weekdays, Saturdays, Sundays andpublic holidays excluded, for one month from today. For further information, please contact: Barry Gold, Azure Holdings plcTel: 07768 948 928 David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th May 20091:00 pmRNSIssue of Equity
30th Apr 20097:00 amRNSTotal Voting Rights
27th Apr 20097:00 amRNSIssue of Equity
16th Apr 20093:05 pmRNSHolding(s) in Company
16th Apr 20097:00 amRNSIssue of Equity
9th Apr 20097:00 amRNSIssue of Equity
6th Apr 20099:59 amRNSHolding(s) in Company
31st Mar 20097:00 amRNSUpdate to the Sale of Shares Agreement
31st Mar 20097:00 amRNSIssue of Equity and Directors' Shareholdings
12th Mar 20097:00 amRNSValiRx Announces Promising In Vivo Data
27th Feb 20097:00 amRNSTotal Voting Rights
13th Feb 200910:52 amRNSResult of EGM
30th Jan 20097:00 amRNSTotal Voting Rights
29th Jan 200912:07 pmRNSAvailability of circular
28th Jan 200911:55 amRNSProposed Reorganisation and General Meeting
5th Jan 20092:50 pmRNSIssue of Equity
31st Dec 20089:00 amRNSTotal Voting Rights
15th Dec 20087:00 amRNSGlobal Distribution Agreement
5th Dec 20082:00 pmRNSChange of Adviser
27th Nov 20084:19 pmRNSIssue of Equity
16th Sep 20087:00 amRNSUpdate on cancer detection test
11th Sep 20087:00 amRNSInterim Results
10th Sep 200810:33 amRNSNotice of Results
18th Aug 20084:02 pmRNSAppointment of director
31st Jul 20087:00 amRNSTotal Voting Rights
28th Jul 20082:48 pmRNSAGM Statement
23rd Jul 20084:02 pmRNSDirector's Dealing
14th Jul 20082:23 pmRNSDirector/PDMR Shareholding
14th Jul 20087:00 amRNSValiRx acquires Cronos Therap
9th Jul 20087:00 amRNSValiRx Acquires Global Rights
30th Jun 20084:38 pmRNSJoint Broker Appointment
30th Jun 20087:00 amRNSFinal Results
26th Jun 20087:00 amRNSTherapeutic Pipeline - in viv
23rd Jun 20088:00 amRNSNotice of Results
5th Jun 20089:13 amRNSHolding(s) in Company
30th May 20087:00 amRNSTotal Voting Rights
15th May 200812:37 pmRNSHolding(s) in Company
12th May 20084:42 pmPRNStatement re Placing of Shares
8th May 20088:05 amRNSIssue of Equity
7th May 20082:20 pmRNSHolding(s) in Company
2nd May 200811:35 amRNSResult of EGM
30th Apr 20087:00 amRNSTotal Voting Rights
7th Apr 20085:13 pmRNSNotice of EGM and Placing
18th Mar 20087:50 amPRNValibio Research Update
13th Feb 20087:55 amPRNLetter of Intent
29th Jan 20087:00 amPRNAustralian GeneICE Patent Granted
23rd Jan 20087:00 amPRNMorphogenesis Update
17th Jan 20087:00 amPRNGeneICE – CRT Research Update
31st Dec 20077:00 amRNSTotal Voting Rights
12th Dec 200711:08 amRNSCollaboration Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.